GA
ANIK icon

Geneva Advisors’s Anika Therapeutics ANIK Stock Holding History

Geneva Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$943K Buy
19,104
+639
+3% +$29.4K 0.02% 372
2017
Q1 		$802K Buy
+18,465
New +$881K 0.01% 401

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Geneva Advisors's ANIK Position: Q2 2017 in Review

Geneva Advisors increased its Anika Therapeutics (ANIK) stake by 3.5% in Q2 2017, buying an estimated $29.4K and bringing the position to 19,104 shares worth $943K. The position accounts for 0.02% of the portfolio, ranked #372.

Geneva Advisors first reported a position in ANIK in Q1 2017 and has held it in 2 quarters since. 159 funds tracked by Wall St. Rank hold ANIK as of Q2 2017.

  • Geneva Advisors held 19,104 shares of Anika Therapeutics worth $943K as of Q2 2017.
  • Geneva Advisors bought 639 Anika Therapeutics shares in Q2 2017, an estimated $29.4K.
  • Anika Therapeutics made up 0.02% of Geneva Advisors's portfolio in Q2 2017, its #372 holding.
  • Geneva Advisors first reported a position in Anika Therapeutics in Q1 2017 and has held it in 2 quarters since.
  • 159 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.